52P - Genetic variation of BCL3 is associated with five-year survival of NSCLC patients

Date 28 March 2014
Event ELCC 2014
Session Lunch and poster display session
Topics Lung and other Thoracic Tumours
Translational Research
Presenter Fotinos-Ioannis Dimitrakopoulos
Citation Journal of Thoracic Oncology (2014) 9 (Supplement 9): S7-S52. 10.1097/JTO.0000000000000131
Authors F.D. Dimitrakopoulos1, A.G. Antonacopoulou1, A.E. Kottorou1, D. Dougenis2, C. Scopa3, H. Papadaki4, H. Kalofonos1
  • 1Molecular Oncology Laboratory, Division Of Oncology, Department Of Internal Medicine, Medical School, University of Patras, 26504 - Patras/GR
  • 2Department Of Cardiothoracic Surgery, Medical School, University of Patras, Patras/GR
  • 3Department Of Pathology, Medical School, University of Patras, Patras/GR
  • 4Department Of Anatomy, Medical School, University of Patras, Patras/GR


BCL3 is an atypical member of the IκB family and it has been found to be overexpressed in hematological malignancies and in some solid tumors, playing a pivotal role in tumor initiation and progression. A tag single nucleotide polymorphism of BCL3 (SNP; rs8100239, T>A) has been identified recently but there are no data relating to its role in non-small cell lung cancer (NSCLC) development.